Morgan Stanley Maintains Overweight on Insmed, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an Overweight rating on Insmed (NASDAQ:INSM) and increased the price target from $40 to $43.
May 10, 2024 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley's positive outlook and price target increase for Insmed suggests confidence in the company's future performance.
Analyst ratings and price target adjustments are significant indicators of a stock's potential future performance. An increase in the price target by a reputable analyst like Morgan Stanley can lead to positive investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100